Somatic TP53 mutations characterize preleukemic stem cells in acute myeloid leukemia

Blood. 2017 May 4;129(18):2587-2591. doi: 10.1182/blood-2016-11-751008. Epub 2017 Mar 3.

Authors

Ridhima Lal¹, Karin Lind¹, Ellen Heitzer², Peter Ulz², Kristina Aubell², Karl Kashofer³, Jan M Middeke⁴, Christian Thiede⁴, Eduard Schulz¹, Angelika Rosenberger¹, Sybille Hofer¹, Birgit Feilhauer¹, Beate Rinner⁵, Vendula Svendova⁶, Michael G Schimek⁶, Frank G Rücker⁷, Gerald Hoefler³, Konstanze Döhner⁷, Armin Zebisch¹, Albert Wölfler¹, Heinz Sill¹

Affiliations

¹ Division of Hematology.
² Institute of Human Genetics, and.
³ Institute of Pathology, Medical University of Graz, Graz, Austria.
⁴ Department of Internal Medicine I, University Hospital Dresden, Dresden, Germany.
⁵ Biomedical Research and.
⁶ Institute for Medical Informatics, Statistics and Documentation, Medical University of Graz, Graz, Austria; and.
⁷ Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany.

PMID: 28258055
DOI: 10.1182/blood-2016-11-751008

No abstract available

Publication types

Clinical Trial
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Female
Humans
Leukemia, Myeloid, Acute / genetics*
Male
Mutation*
Tumor Suppressor Protein p53 / genetics*

Substances

TP53 protein, human
Tumor Suppressor Protein p53